Atara Biotherapeutics Inc Asset Resilience Ratio
Atara Biotherapeutics Inc asset resilience ratio. Atara Biotherapeutics Inc (ATRA) has an Asset Resilience Ratio of 26.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Atara Biotherapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Atara Biotherapeutics Inc (2014–2024)
Asset resilience ratio of Atara Biotherapeutics Inc from 2014 to 2024. This chart shows how Atara Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Atara Biotherapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Atara Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Atara Biotherapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.97 Million | 26.42% |
| Total Liquid Assets | $7.97 Million | 26.42% |
Asset Resilience Insights
- Very High Liquidity: Atara Biotherapeutics Inc maintains exceptional liquid asset reserves at 26.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atara Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Atara Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Atara Biotherapeutics Inc Asset Resilience Ratio by Year (2014–2024)
Atara Biotherapeutics Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Atara Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.01% | $17.47 Million | $109.10 Million | +0.37pp |
| 2023-12-31 | 15.64% | $25.88 Million | $165.50 Million | -24.18pp |
| 2022-12-31 | 39.82% | $149.88 Million | $376.42 Million | -16.79pp |
| 2021-12-31 | 56.61% | $264.98 Million | $468.13 Million | +5.55pp |
| 2020-12-31 | 51.05% | $300.25 Million | $588.12 Million | -2.83pp |
| 2019-12-31 | 53.88% | $184.79 Million | $342.94 Million | -9.65pp |
| 2018-12-31 | 63.53% | $248.93 Million | $391.84 Million | +23.64pp |
| 2017-12-31 | 39.89% | $86.87 Million | $217.78 Million | -38.81pp |
| 2016-12-31 | 78.71% | $207.71 Million | $263.91 Million | -12.61pp |
| 2015-12-31 | 91.31% | $296.74 Million | $324.98 Million | +13.83pp |
| 2014-12-31 | 77.48% | $82.22 Million | $106.12 Million | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more